Tostitos tortilla chips recalled after they may have been contaminated, Frito-Lay says
Frito-Lay
issued a recall
of some bags of Tostito's tortilla chips, saying the snack foods may have been contaminated with undeclared products.
The recall applies to 13-ounce bags of the company's Tostitos Cantina Traditional Yellow Corn Tortilla Chips. The bags could include nacho cheese tortilla chips and therefore may contain undeclared milk allergens, the company
said in a news release
distributed by the
U.S. Food and Drug Administration
.
The product is safe to consume for people who do not have a dairy allergy or milk sensitivity, Frito-Lay
said in a statement
. The company said no allergic reactions have been reported in connection with the recall.
The recall affects less than 1,300 bags of chips, according to the news release. The full list of affected lot numbers is available on the FDA's website.
The chips were sold at multiple stores and online in 13 states: Alabama, Florida, Georgia, Illinois, Indiana, Kentucky, Mississippi, North Carolina, Ohio, South Carolina, Tennessee, Virginia and West Virginia. They would have been sold as early as March 7, the company said,. The recall was announced on March 27.
The recall does not apply to any other Tostitos product, flavors, bag sizes or variety packs, the company said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
RFK Jr. will ‘end the war' against alternative medicine at the FDA, from stem cell therapy to chelation. Here's what to know
Health and Human Services Secretary Robert F. Kennedy, Jr. doubled down on his support for non-pharmaceutical health treatments during a recent podcast appearance, saying, 'We're going to end the war at the FDA against alternative medicine.' Speaking on the Ultimate Human podcast with host Gary Brecka, a 'renowned Human Biologist, biohacker, and longevity expert,' according to the website, Kennedy said he would fix the U.S. Food and Drug Administration's bias against the following: stem cell treatments, chelating drugs, vitamins and minerals, amino acids, peptides, and hyperbaric chambers. 'Our position is that the FDA has a job: Just do the science on these kinds of issues and then tell the public what they've learned from the science … but don't tell physicians what they can and cannot prescribe,' he said. And as far as the patients go, he said, 'If you want to take an experimental drug … you ought to be able to do that.' RFK Jr. added, 'We don't want to have the Wild West. We want to make sure that information is out there. But we also want to respect the intelligence of the American people' to decide what treatments will benefit them the most. He acknowledged that, with this approach, there will be 'charlatans' as well as 'people who have bad results' from various alternative treatments. 'But ultimately,' he said, 'you can't prevent that either way, and leaving the whole thing in the hands of pharma is not working for us.' Brecka called Kennedy's pronouncements 'music to my ears.' Below, what you need to know about the alternative therapies RFK Jr. is advocating for. What is it: It's a way to repair diseased or injured tissue in the body using stem cells—cells that can self-renew or become other types of tissues—typically grown in a lab, manipulated, and then be implanted into the patient. What it does: Though it's considered to be largely experimental, the FDA does permit stem cell therapies for blood and immune disorders. Leukemia, lymphoma, neuroblastoma, and multiple myeloma, for example, are also often treated this way, with bone marrow treatments, which are backed by decades of science. Other types of the treatment are still in clinical trials, while more and more wellness centers are offering the treatment for unapproved reasons, using cells drawn from the patient's body and injected back in without manipulation for everything from autism and ALS to Parkinson's and better skin, according to the New York Times. Kennedy told Brecka that he received the treatment for his voice disorder, spasmodic dysphonia, and that it helped him 'enormously,' but that he had to go to Antigua to access it. Risks: For starters, wellness clinic treatments cannot guarantee they are using actual stem cell, reported the Times. And improper injections can lead to a host of terrible consequences—clots, infections, blindness, and even the formation of tumors, which the FDA warned of in 2021. What it is: Chelation involves the use of certain chemicals to remove toxic heavy metals, such as mercury and lead, from the body; all FDA-approved chelation therapy products require a prescription and can only be used safely under the supervision of a healthcare practitioner. What it does: Some alternative medicine practitioners offer chelation therapy, through pill or injection, as a way to treat Alzheimer's, autism, diabetes, high blood pressure, or Parkinson's disease, all of which are unapproved and risky. Children's Health Defense, founded by Kennedy, has written about chelation as a way to treat autism, which compares 'autism with mercury poisoning' due to childhood vaccines that contained the preservative thimerosal (largely mercury) before it was removed in 2001. Some flu shots still contain the preservative, but, says the Centers for Disease Control and Prevention, 'There is no evidence of harm caused by the low doses of thimerosal in vaccines.' Risks: The FDA warns specifically about using chelation therapy for autism, and notes, 'Chelating important minerals needed by the body can lead to serious and life-threatening outcomes.' While minor risks may include fever, headache, muscle pain, and nausea or vomiting, severe reactions range from heart failure and kidney damage to respiratory failure and seizures, according to the Cleveland Clinic. What they are: Dietary supplements in almost every letter of the alphabet, from A to zinc, are over-the-counter pills or liquids that contain nutritional boosts of vitamins and minerals. What they aim to help: Vitamin and mineral supplements aim to fill in with necessary nutrients that a person is not getting through food—though nutritionists believe that healthy food is the best source of such vitamins and minerals. Studies have found supplements may help with practically any issue under the sun—energy, heart issues, cognitive function, gut health, sleep, and more. Risks: The U.S. Food and Drug Administration regulates supplements, but doesn't approve them for safety or effectiveness before they are sold to the public. Some may cause liver damage and toxicity, while others may just be a waste of money. What it is: Amino acids are often referred to as the 'building blocks of proteins,' needed for building proteins, hormones, and neurotransmitters. are compounds that play many critical roles in your body. You need them for vital processes such as building proteins, hormones, and neurotransmitters. Amino acids are concentrated in protein-rich foods such as meat, fish, and soybeans, and foods that contain all nine essential amino acids are called complete proteins. Peptides are short proteins, and come in the form of hormones such as follicle-stimulating hormone (FSH), and creatine and collagen. What they aim to help: Amino acid supplements may help with various issues—such as L-arginine for blood flow and inflammation; tryptophan for mood and sleep; and valine, leucine, and isoleucine to help with energy and athletic performance. Taking collagen supplements may help strengthen nails and bones, while people take creatine for boosting workouts and building muscle growth. Risks: Side effects of taking either can range from toxicity and gastrointestinal issues to effects on brain function muscle protein balance. Creatine may cause muscle cramps and digestive problems (and may not have many benefits), while tryptophan may cause dizziness, headache, or nausea. And again, as with all supplements, the U.S. Food and Drug Administration regulates them, but doesn't approve them for safety or effectiveness before they are sold to the public. What it is: Hyperbaric oxygen therapy in a medical-grade, FDA-approved chamber lets you breathe pure oxygen—as opposed to everyday air, which is just 21% oxygen mixed with nitrogen. Hyperbaric oxygen is also highly pressurized, thereby allowing the lungs to take more in. Home chambers (used by folks including Lebron James, LeAnn Rimes, and Mayim Bialik), as well as those offered in many wellness clinics, do not deliver 100% oxygen. Instead, they use regular air that is 30% more pressurized than normal for what's known as 'mild hyperbarics.' What it aims to help: The FDA has been regulating HBOT chambers since 1976, and has officially cleared 13 medical conditions—such as decompression sickness, burns, radiation injury, and certain wounds—for such treatment. But it's used off-label for many other reasons, including concussions, traumatic brain injury, long COVID, age reversal, stroke recovery, fibromyalgia, and improved brain function, many of which are being looked at in ongoing clinical trials. Risks: For medical-grade chambers, risks include ear and sinus pain, middle ear injuries, temporary vision changes, and lung collapse, which is rare, according to the FDA. For mild hyperbarics, risks include potential exposure to toxic oils from some compressors, carbon dioxide buildup that brings a risk of hypoxia inside the chamber—or, according to some experts and a body of inconclusive evidence, that the treatment may simply be ineffective. This story was originally featured on
Yahoo
8 hours ago
- Yahoo
Popular Aldi snack recalled due to potential ‘life-threatening' allergen
Aldi is recalling one of its sweet treats due to the presence of an undeclared allergen. The U.S. Food and Drug Administration (FDA) issued a notice on Tuesday to announce that Camerican International was recalling 7.05 oz boxes of Casa Mamita Churro Bites Filled with Chocolate Hazelnut Cream. The recall was issued because the Aldi brand snack may contain undeclared milk, so consumers with an allergy or 'severe sensitivity to milk run the risk of serious or life-threatening allergic reaction,' per the FDA. The recalled churro bites were distributed at Aldi stores in 13 states: Alabama, Arkansas, Florida, Georgia, Iowa, Illinois, Kentucky, Louisiana, Missouri, Mississippi, North Carolina, South Carolina, and Tennessee. The 7.05 oz cardboard boxes are marked with a 'Best If Used By' date of July 14, 2025, and the Lot Number '01425.' According to the FDA, the recall was initiated after a 'consumer discovered that the milk-containing product was distributed in packaging that did not reveal the presence of milk.' A subsequent investigation revealed the mistake was a result of a 'temporary breakdown in the company's production and packaging processes,' which has since been corrected. However, there have been no illnesses reported to date due to this product. Consumers are now urged to return the churro bites to the place of purchase for a full refund. This isn't the first time Aldi food item to be recalled recently. In May, Santa Monica Seafood of Rancho Dominguez, California, issued a voluntary recall on its Atlantic Salmon Portions with Seafood Stuffing because they may have contained undeclared soy. The affected salmon portions were sold in three states: California, Nevada, and Arizona. The products were sold in 16-ounce packages and had a use/freeze-by date of June 2, 2025. The last two years have also seen an alarming and unexplained rise in recalls. In 2024, approximately 300 food recalls were issued, with those recalls being linked to nearly 1,400 illnesses, a Public Interest Research Group report revealed. Out of the 1,400 illnesses, 487 people became sick enough to require hospitalization, and 19 people died. While those numbers are still low when weighed against the entire U.S. population, they are also double the number of hospitalizations and deaths from food-borne illnesses in 2023. Earlier in May, cucumbers sold across the country were recalled after people in 15 states reported getting ill from salmonella. Florida-based Bedner Growers, Inc. recalled the vegetables distributed by Fresh Start Produce Sales, Inc. from April 29 to May 19.
Yahoo
14 hours ago
- Yahoo
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting
Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline 83% of subjects maintained a clinically meaningful benefit with a 3 or more point improvement in Revised Venous Clinical Severity Score (rVCSS) 9.1 point average rVCSS improvement among the clinically meaningful benefit cohort Subjects experienced a median 74% improvement in leg pain Interim follow-up data indicate sustained improvements across all venous-specific quality-of-life (QoL) indicators A decision from the U.S. Food and Drug Administration (FDA) on the VenoValve is anticipated in the second half of 2025 Company to host live webcast with presenting Principal Investigator, today, June 6th at 11:20 AM ET / 10:20 AM CT - Access the Webcast Here IRVINE, CA / / June 6, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that interim two-year follow-up data on 42 subjects from the 75 person VenoValve U.S. pivotal trial will be presented today by lead enroller Dr. Cassius Iyad Ochoa Chaar, at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting (VAM25) being held June 4-7, 2025 in New Orleans, LA. Additionally, the Company announced it will host a live webcast to discuss these interim results today, Friday, June 6th at 11:20 AM ET / 10:20 AM CT (details below). Key interim two-year follow-up data being presented at VAM25 include: 83.3% of subjects (n=35/42) maintained a clinically meaningful benefit, defined as an improvement of 3 or more points in the revised Venous Clinical Severity Score (rVCSS). 9.1 point average rVCSS improvement among the responder cohort. A median 74% improvement in leg pain, as measured by the Visual Analog Scale (VAS). Wound healing outcomes in 17 subjects with 25 ulcers showed that 60% of ulcers healed completely, 24% decreased in size, and 16% increased in size. Patient-reported outcomes also demonstrated sustained improvements across all venous specific QoL indicators (VEINES-QoL/Sym). Among the subjects (n=30), a 100% valve patency rate. All values were calculated comparing each patient's baseline levels to the reported values at the patient's 24-month visit. The Revised Venous Clinical Severity Score (rVCSS) is a clinically validated scoring system used to track the progression or regression of venous diseases. "These interim two-year follow-up data demonstrate substantial and sustained improvement across all effectiveness endpoints at two years. This is extremely encouraging, especially when you consider that all the patients enrolled in the study had severe CVI and failed all other treatment options," said Robert Berman, enVVeno Medical's Chief Executive Officer. "Despite attempts over many decades, nobody has been able to create an effective treatment for severe CVI caused by malfunctioning valves in the deep veins of the leg. The VenoValve has the potential to change the treatment paradigm for deep venous CVI, both for the millions of patients suffering from severe CVI and the thousands of vascular surgeons who have been waiting for an effective treatment option." Dr. Cassius Iyad Ochoa Chaar, who is the Associate Professor of Surgery, Division of Vascular Surgery and Endovascular Therapy, Yale School of Medicine, will present the abstract titled, "Patients with Deep Venous Reflux Continue to Experience Clinical Improvement 2-year after Implantation of the VenoValve" today at VAM 2025. The VenoValve is a potential first-in-class, surgical replacement venous valve for patients with severe deep venous CVI. The Company estimates that there are approximately 2.5 million potential new patients each year in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the U.S. Food and Drug Administration (FDA), with a decision anticipated in the second half of 2025. Webcast Details The Company will host a webcast presentation to discuss the results for investors, analysts and other interested parties today, June 6, 2025, at 11:20 AM ET / 10:20 AM CT. Joining enVVeno management for the event will be Dr. Chaar. The live webcast will be accessible on the Events page of the enVVeno website, and will be archived for 90 days. About CVI Severe, deep venous Chronic Venous Insufficiency (CVI) is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of severe CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. Estimates indicate that CVI costs the U.S. healthcare system in excess of $4 billion each year. About enVVeno Medical Corporation enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe. Cautionary Note on Forward-Looking Statements This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. INVESTOR CONTACT:Jenene Thomas, JTC Team, LLCNVNO@ 824-0775 MEDIA CONTACT:Glenn Silver, FINN 818-8198 SOURCE: enVVeno Medical Corporation View the original press release on ACCESS Newswire
